Mara Goldstein
Stock Analyst at Mizuho
(2.80)
# 1,958
Out of 5,044 analysts
77
Total ratings
44.83%
Success rate
8.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $10.51 | +185.44% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.19 | +356.62% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $8.85 | -9.60% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $19.88 | +111.27% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $14.25 | +250.88% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.51 | +233.09% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $91.65 | -15.98% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.44 | +186.89% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.49 | +436.91% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.53 | +2,146.35% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $60.92 | +47.73% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.59 | -53.89% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.10 | +17,042.86% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.49 | +208.17% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $87.03 | +49.37% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $3.32 | -39.76% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.54 | +679.22% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.06 | +15,444.04% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $61.97 | -67.73% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $8.78 | +446.70% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.06 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.11 | +173.97% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $10.51
Upside: +185.44%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.19
Upside: +356.62%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $8.85
Upside: -9.60%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $19.88
Upside: +111.27%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $14.25
Upside: +250.88%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.51
Upside: +233.09%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $91.65
Upside: -15.98%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.44
Upside: +186.89%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.49
Upside: +436.91%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.53
Upside: +2,146.35%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $60.92
Upside: +47.73%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.59
Upside: -53.89%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.10
Upside: +17,042.86%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.49
Upside: +208.17%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $87.03
Upside: +49.37%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $3.32
Upside: -39.76%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.54
Upside: +679.22%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.06
Upside: +15,444.04%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $61.97
Upside: -67.73%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $8.78
Upside: +446.70%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $27.06
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.11
Upside: +173.97%